Related Content
Search Google Scholar for:
|
|
Science 27 July 1990:
Vol. 249. no. 4967, pp. 423 - 425
DOI: 10.1126/science.1696030
|
|
Articles
Science, Vol 249, Issue 4967, 423-425
Copyright © 1990 by American Association for the Advancement of Science
Use of prior vaccinations for the development of new vaccines
HM Etlinger,
D Gillessen,
HW Lahm,
H Matile,
HJ Schonfeld,
and
A Trzeciak
Central Research Unit F. Hoffmann-La Roche, Basel, Switzerland.
There is currently a need for vaccine development to improve the immunogenicity of protective epitopes, which themselves are often poorly immunogenic. Although the immunogenicity of these epitopes can be enhanced by linking them to highly immunogenic carriers, such carriers derived from current vaccines have not proven to be generally effective. One reason may be related to epitope-specific suppression, in which prior vaccination with a protein can inhibit the antibody response to new epitopes linked to the protein. To circumvent such inhibition, a peptide from tetanus toxoid was identified that, when linked to a B cell epitope and injected into tetanus toxoid-primed recipients, retained sequences for carrier but not suppressor function. The antibody response to the B cell epitope was enhanced. This may be a general method for taking advantage of previous vaccinations in the development of new vaccines.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
- Tetanus vaccination and risk of multiple sclerosis: a systematic review..
- M. A. Hernan, A. Alonso, and S. Hernandez-Diaz (2006)
Neurology
67, 212-215
| Abstract »
| Full Text »
| PDF »
- Combined Conjugate Vaccines: Enhanced Immunogenicity with the N19 Polyepitope as a Carrier Protein.
- K. Baraldo, E. Mori, A. Bartoloni, F. Norelli, G. Grandi, R. Rappuoli, O. Finco, and G. Del Giudice (2005)
Infect. Immun.
73, 5835-5841
| Abstract »
| Full Text »
| PDF »
- Virus-Like Particles as Carriers for T-Cell Epitopes: Limited Inhibition of T-Cell Priming by Carrier-Specific Antibodies.
- C. Ruedl, K. Schwarz, A. Jegerlehner, T. Storni, V. Manolova, and M. F. Bachmann (2005)
J. Virol.
79, 717-724
| Abstract »
| Full Text »
| PDF »
- N19 Polyepitope as a Carrier for Enhanced Immunogenicity and Protective Efficacy of Meningococcal Conjugate Vaccines.
- K. Baraldo, E. Mori, A. Bartoloni, R. Petracca, A. Giannozzi, F. Norelli, R. Rappuoli, G. Grandi, and G. Del Giudice (2004)
Infect. Immun.
72, 4884-4887
| Abstract »
| Full Text »
| PDF »
- Identification of B- and T-Cell Epitopes of BB, a Carrier Protein Derived from the G Protein of Streptococcus Strain G148.
- L. Goetsch, J. F. Haeuw, T. Champion, C. Lacheny, T. N'Guyen, A. Beck, and N. Corvaia (2003)
Clin. Vaccine Immunol.
10, 125-132
| Abstract »
| Full Text »
| PDF »
- Flexibility in MHC and TCR Recognition: Degenerate Specificity at the T Cell Level in the Recognition of Promiscuous Th Epitopes Exhibiting No Primary Sequence Homology.
- S. K. Joshi, P. R. Suresh, and V. S. Chauhan (2001)
J. Immunol.
166, 6693-6703
| Abstract »
| Full Text »
| PDF »
- Carrier Properties of a Protein Derived from Outer Membrane Protein A of Klebsiella pneumoniae.
- I. Rauly, L. Goetsch, J.-F. Haeuw, C. Tardieux, T. Baussant, J.-Y. Bonnefoy, and N. Corvaia (1999)
Infect. Immun.
67, 5547-5551
| Abstract »
| Full Text »
| PDF »
- A Fully Synthetic Immunogen Carrying a Carcinoma-associated Carbohydrate for Active Specific Immunotherapy1.
- R. Lo-Man, S. Bay, S. Vichier-Guerre, E. Deriaud, D. Cantacuzene, and C. Leclerc (1999)
Cancer Res.
59, 1520-1524
| Abstract »
| Full Text »
| PDF »
- Carrier-Induced, Hapten-Specific Suppression: A Problem of Antigen Presentation?.
- X. Renjifo, S. Wolf, P.-P. Pastoret, H. Bazin, J. Urbain, O. Leo, and M. Moser (1998)
J. Immunol.
161, 702-706
| Abstract »
| Full Text »
| PDF »
- Progress toward malaria preerythrocytic vaccines.
- S. Hoffman, V Nussenzweig, J. Sadoff, and R. Nussenzweig (1991)
Science
252, 520-521
| PDF »
|
|
